Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 0.37 |
| ▸ | TNKS | O95271 | 4/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | TACR3 | P29371 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ERG | P11308 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314998 | 1.00 | TNKS2 (0.37) | TNKS2TNKSTGFBR1APLNRMAPK14 | |
| SCHEMBL314997 | 1.00 | TNKS2 (0.37) | TNKS2TNKSTGFBR1APLNRMAPK14 | |
| SCHEMBL314321 | 0.91 | TACR3 (0.38) | APLNRTACR3 | |
| SCHEMBL12654553 | 0.87 | TNKS2 (0.39) | TNKS2TNKSTGFBR1APLNRTACR3 | |
| SCHEMBL314485 | 0.87 | MAPT (0.40) | TNKS2TNKSAPLNRGLAL3MBTL1 | |
| SCHEMBL314484 | 0.87 | MAPT (0.40) | TNKS2TNKSAPLNRGLAL3MBTL1 | |
| SCHEMBL314483 | 0.87 | MAPT (0.40) | TNKS2TNKSAPLNRGLAL3MBTL1 | |
| SCHEMBL313824 | 0.85 | TNKS2 (0.40) | TNKS2TNKSTGFBR1MAPK14TACR3 | |
| SCHEMBL314758 | 0.85 | TNKS2 (0.40) | TNKS2TNKSTGFBR1MAPK14TACR3 | |
| SCHEMBL314133 | 0.85 | TNKS2 (0.40) | TNKS2TNKSTGFBR1TACR3ERG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966211-B1 | TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-12-26 | — | — | EP | claimed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | claimed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | claimed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| EP-1966211-B1 | TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-12-26 | — | — | EP | disclosed |
| EP-1966211-B1 | TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| EP-1966211-A1 | TRIAZOLE DERIVATIVES | Merck Patent GmbH (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007079820-A1 | TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007079820-A1 | TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306042-A1 | Triazole Derivatives | TGFBR1, TGFBR2, SMAD3 | TNKS2 630/4885TNKS 534/4885TGFBR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.